2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2259

Limitations of Current Treatment for Systemic Lupus Erythematosus: A Patient and Physician Survey
Abstract Number: 1459

Limited Utility of Pulmonary Function Tests and B-Type Natriuretic Peptide As Screening Tools for Pre-Capillary Pulmonary Hypertension in Patients with Systemic Sclerosis
Abstract Number: 714

Line Blot Assay, a Screening Test for Autoantibodies in Systemic Sclerosis (SSc)
Abstract Number: 1268

Lipid Alterations and Measurement of Arterial Stiffness in Rheumatoid Arthritis
Abstract Number: 1265

Lipoprotein Subclass Particles and Small Vessel Elasticity As a Potential Marker for Early Atherosclerosis in Rheumatoid Arthritis: a Prospective, Controlled Study
Abstract Number: 348

Liver Fibrosis Evaluated by Shearwave Elastograpy Is Associated with Body Mass Index and Serum AST, but Not Methotrexate Cumulative Dose and Duration in Patients with Rheumatoid Arthritis
Abstract Number: 1822

Liver Toxicity Monitoring and Its Impact On Methotrexate Discontinuation in a National Cohort of Veterans
Abstract Number: 2612

Localisation of Bone Marrow Edema in Sacroiliac Joints in Spondyloarthritis Patients: Does the Site of Lesions Change Over a 3-Month Period?
Abstract Number: 1020

Location of Erosions At the Metatarsophalangeal Joints in Patients with Rheumatoid Arthritis
Abstract Number: 1582

Long Term Costs and Cost-Effectiveness of an Integrated Rehabilitation Programme for Chronic Knee Pain
Abstract Number: 574

Long Term Inhibition of Interleukin (IL)-17A with Secukinumab Improves Clinical Symptoms and Reduces Spinal Inflammation As Assessed by Magnetic Resonance Imaging in Patients with Ankylosing Spondylitis
Abstract Number: 227

Long Term Outcome of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies and Amyopathic Dermatomyositis
Abstract Number: 41

Long-Distance Physical Connections Between Chondrocytes; Cell-to-Cell Communication within Articular Cartilage
Abstract Number: 1318

Long-Term Benefits of 4-Weekly Certolizumab Pegol Combination and Monotherapy On Household Productivity and Social Participation in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study
Abstract Number: 2195

Long-Term Changes in Autoantibody Profile After Pandemic Unadjuvanted Influenza A/H1N1 Vaccine in Sjögren’s Syndrome

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].